title: FDA LABA warning: is there anything new here?
abstract: The FDA advisory on long-acting beta-agonists (LABAs) is not based on new data but on ongoing safety concerns about this class of medication. Not to be ignored are the potential safety risks of short-acting beta-agonists (SABAs).
authors.affiliation: Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. scott.weiss@channing.harvard.edu
authors.forename: S T
authors.initials: ST
authors.lastname: Weiss
mesh_terms: D000280:Administration, Inhalation; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy; D003692:Delayed-Action Preparations; D004348:Drug Labeling; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D017410:Practice Guidelines as Topic; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000318:Adrenergic beta-Agonists; D003692:Delayed-Action Preparations; D005938:Glucocorticoids